EMA hits record high in vet medicine nods for second year running
EMA recommended 30 veterinary medicines for marketing authorisation in 2025
EMA recommended 30 veterinary medicines for marketing authorisation in 2025
Myqorzo, a selective small-molecule cardiac myosin inhibitor, is designed to improve functional capacity and relieve symptoms in oHCM
The injectable borofalan (10B), developed by CNNC Headway—a subsidiary of China Isotope & Radiation Corporation (CIRC) under the China National Nuclear Corporation (CNNC)—has officially entered Phase I clinical trials
The trial also revealed statistically significant and clinically meaningful gains in key patient-reported outcomes
Developed using STEERLife’s proprietary FragMelt continuous processing platform, the approval marks a major breakthrough in pharmaceutical manufacturing
Preclinical studies show that 4P004 modulates multiple biological markers across the joint, potentially slowing structural damage while improving function
The clearance marks a major step in Diabeloop’s ambition to become a central partner for insulin pump manufacturers and expand access to automated insulin delivery in the US market
The current two-vial format requires healthcare professionals to mix a lyophilised antigen with a liquid adjuvant before administration
The approval is backed by data showing deep, durable responses and manageable tolerability
Subscribe To Our Newsletter & Stay Updated